Lectus Therapeutics Limited (Lectus; www.lectustherapeutics.com), an emerging UK-based bio-pharmaceutical company focused on the discovery and development of next-generation ion channel modulators, announced today it had secured a strategic investment from Takeda Research Investment Inc. (TRI) to advance its core ion channel drug discovery and development programmes. Full details of the terms of the strategic partnership between Lectus and TRI were not disclosed.
